VQW 765
Alternative Names: AQW-051; VQW-765Latest Information Update: 06 Dec 2022
Price :
$50 *
At a glance
- Originator Novartis
- Developer Novartis; Vanda Pharmaceuticals
- Class Antipsychotics
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cognition disorders; Drug-induced dyskinesia; Phobic disorders
Most Recent Events
- 02 Dec 2022 Efficacy data from a phase II trial in Phobic disorders released by Vanda Pharmaceuticals
- 03 Aug 2022 Vanda Pharmaceuticals completes enrolment in its phase II trial in Phobic disorders (In adults, In the elderly) in USA (PO) (NCT04800237)
- 02 Aug 2022 Vanda Pharmaceuticals completes phase II trial in Phobic disorders (In adults, In the elderly) in USA (PO) (NCT04800237)